Drugs / Anricofen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07376577 | Jan 2026 → Mar 2028 expected | — | The First Affiliated Hospital of Xinxiang Medical College | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anricofen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07376577 ↗ |
| Action | Activate | “κ-opioid receptor agonist” NCT07376577 ↗ |
| Modality | Other / unclassified | “Anricofen is a novel peripherally selective κ-opioid receptor agonist” NCT07376577 ↗ |
| Route | Intravenous | “It is administered intravenously.” NCT07376577 ↗ |